Court bans Krka's marketing of esomeprazole in Austria
This article was originally published in Scrip
The commercial court in Vienna has imposed a temporary injunction on marketing any product containing esomeprazole (AstraZeneca's treatment for stomach acid-related diseases Nexium) enantiomers with optical purity of more than 99.8% by Krka in Austria after AstraZeneca alleged that its patent EP 1020461 had been infringed.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.